Combating Illicit Xylazine: New Penalties and Control of Veterinary Substance
This Act designates illicit xylazine use as an urgent public health threat, particularly when mixed with illegal drugs like fentanyl. It establishes severe penalties for the unlawful distribution and human use of xylazine, aiming to curb its proliferation and save lives. Citizens should be aware that this substance, which currently lacks an FDA-approved human antidote, is now subject to strict legal enforcement within the context of illegal drug trafficking.
Key points
Xylazine (a veterinary sedative) is declared an 'emerging drug threat' in the United States.
The Act prohibits any use of xylazine in humans and any use that is not explicitly licensed (e.g., for veterinary purposes).
Illegal distribution and importation of xylazine are now penalized under the Controlled Substances Act, similar to other illicit narcotics.
Federal agencies (DEA and FDA) are required to track and report to Congress on the prevalence, origin, and spread of illicit xylazine.
Expired
Citizen Poll